SCHEMBL4024940

SCHEMBL4024940

CC(C)(C)OC(=O)N1CCC(Cc2ccccc2)(c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)CC1

nearest known ligand 0.50

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 8/20 0.45
MAPK13 O15264 5/20 0.45
MAPK12 P53778 5/20 0.45
MAPK11 Q15759 5/20 0.45
GCGR P47871 3/20 0.45
ALOX5 P09917 4/20 0.43
BRAF P15056 1/20 0.42
CYP46A1 Q9Y6A2 1/20 0.41
TGFBR1 P36897 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4025346 0.89 MAPK14 (0.44) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL8654800 0.88 MAPK14 (0.51) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL4027443 0.85 BRAF (0.49) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL13810824 0.78 MAPK14 (0.56) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL4027276 0.78 MAPK14 (0.56) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL4024937 0.76 OPRD1 (0.44) CYP46A1
SCHEMBL4025352 0.76 CSNK1A1 (0.60) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL4584849 0.76 CSNK1A1 (0.60) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL27450957 0.74 MAPK13 (0.50) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL4025777 0.74 BRAF (0.47) MAPK14MAPK13MAPK12MAPK11GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0854870-B1 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY MERCK & CO INC (US) 2009-06-10 EP claimed
EP-0854870-B1 SUBSTITUTED IMIDAZOLES HAVING ANTI-CANCER AND CYTOKINE INHIBITORY ACTIVITY MERCK & CO INC (US) 2009-06-10 EP disclosed
US-6083949-A FOR TREATING CANCER IN WHICH RAF KINASE IS IMPLICATED, AS WELL AS COMPOUNDS WHICH INHIBIT, SUPPRESS OR ANTAGONIZE THE PRODUCTION OR ACTIVITY OF CYTOKINES SUCH AS INTERLEUKINS AND TUMOR NECROSIS FACTOR MERCK & CO., INC. (US) 2000-07-04 US disclosed